The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...

EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) Roche will continue its ...

Sarepta said it accepts the CHMP decision on Elevidys, while partner Roche said it will continue working with the EMA.

Stock futures nudged higher on Friday, driven by strong performances from major technology companies and growing optimism over potential trade agreements ahead of the Trump administration’s August ...